Your appetite dropped significantly and now you are at risk of vitamin deficiencies
More recently, long-acting GLP-1 RAs for obesity have been approved: semaglutide (approved in 2021), resulted in an average weight reduction of around 15% 1214 , and tirzepatide (approved in 2023), demonstrating an average weight reduction of approximately 20% 1517
Intramuscular injection should be used only when this route of administration is necessary, and repeated injections at the same site should be avoided
You (or your caregiver) inject it in one of three areas: the abdomen, thigh, or upper arm, and it can be taken without regard to meals (any time of day thats convenient, on the same day each week)
Its wise to keep in mind that while the medications can help a person lose weight, overweight and obesity are complex diseases, and lifestyle modifications like diet and exercise are needed to maximize successful long-term weight management and overall health
Studies are needed into the possibilities of the drug, and also into the possible negative side effects